Navigating FDA’s 2026 Guidance on Demonstrating Substantial Evidence of Effectiveness: Key Insights for Successful NDA and BLA Submissions
Date: Sept 16, 2026
Duration: 60 Minutes
Time: 12 PM EST
Clinical evidence has always been the cornerstone of successful NDA and BLA approvals. But as drug development continues to evolve—with advances in precision medicine, innovative trial designs, biomarkers, and real-world evidence—the FDA is also reshaping how it evaluates whether a product has demonstrated substantial evidence of effectiveness.
The FDA’s 2026 draft guidance introduces a more modern and flexible approach to assessing clinical evidence. Instead of relying primarily on the traditional expectation of two pivotal clinical trials, the Agency emphasizes evaluating the totality of evidence. This means considering the overall strength, quality, consistency, and scientific credibility of the available data when determining whether a drug or biologic has demonstrated effectiveness.
Understanding these evolving expectations is essential for sponsors planning clinical development programs, designing pivotal studies, engaging with the FDA, or preparing NDA and BLA submissions. Decisions made early in development can have a significant impact on the strength of the final evidence package and, ultimately, the success of a marketing application.
In this webinar, the speaker Dr. Mukesh Kumar will break down the new guidance into practical, real-world strategies that regulatory and clinical professionals can immediately apply. Through scientific explanations, regulatory insights, and practical examples, you’ll gain a clear understanding of what the guidance means, why it matters, and how to align your development program with FDA’s latest thinking.
Whether you’re developing a new therapeutic product, supporting clinical trials, or preparing regulatory submissions, this session will help you strengthen your evidence strategy, improve regulatory decision-making, and reduce the risk of avoidable delays during FDA review.
What You Will Learn
During this comprehensive webinar, participants will explore:
- Scientific principles underlying FDA’s revised substantial evidence framework
- Key differences between previous FDA expectations and the 2026 draft guidance
- When one adequate and well-controlled clinical trial may be sufficient
- Understanding confirmatory evidence and its role in regulatory decision-making
- Factors influencing FDA’s assessment of the strength of clinical evidence
- Designing clinical development programs aligned with FDA expectations
- Statistical considerations supporting substantial evidence
- Integrating biomarkers, external evidence, and modern clinical methodologies
- Implications for IND planning, End-of-Phase meetings, and NDA/BLA submissions
- Common regulatory pitfalls that weaken evidence packages
- Practical case studies illustrating successful evidence strategies
- Preparing regulatory submissions that withstand FDA scientific review
Why You Should Attend
The FDA’s revised draft guidance has the potential to influence how sponsors plan, execute, and defend their clinical development programs for years to come. Understanding these changes now can help your organization make better scientific and regulatory decisions before critical milestones are reached.
In this webinar, you’ll gain practical insights into how the guidance may impact study design, endpoint selection, statistical planning, confirmatory evidence, and FDA interactions. Through real-world regulatory perspectives and practical examples, you’ll learn how to identify potential challenges early, build stronger evidence packages, and better prepare for NDA and BLA submissions.
Whether you work in regulatory affairs, clinical development, medical writing, biostatistics, or clinical operations, this session will equip you with actionable knowledge that you can immediately apply to ongoing and future development programs.
Speaker: Mukesh Kumar
PhD, RAC | CEO, FDAMap
For more info, fill the box below. We will contact you within 24 hrs.
Who Should Attend?
This webinar is ideal for:- Regulatory Affairs Professionals
- Clinical Development Scientists
- Clinical Project Managers
- Clinical Operations Professionals
- Medical Directors
- Clinical Research Associates (CRAs)
- Biostatisticians
- Medical Writers
- Clinical Data Management Professionals
- Pharmacovigilance Specialists
- Quality Assurance Professionals
- CRO Leadership
- Pharmaceutical & Biotechnology Companies
- Drug Development Startups
- IND Sponsors
- NDA/BLA Submission Teams
- Regulatory Consultants
Key Takeaways
After attending this webinar, you will be able to:
- Interpret FDA’s revised substantial evidence framework with confidence.
- Apply FDA’s latest recommendations to clinical development planning.
- Develop scientifically robust evidence packages for regulatory submissions.
- Understand when a single clinical investigation with confirmatory evidence may be appropriate.
- Improve regulatory interactions and submission quality.
- Reduce development risks through proactive regulatory strategy.
- Position your organization for successful FDA review under evolving regulatory expectations.
Meet Your Speaker
Dr. Mukesh Kumar is an internationally recognized FDA regulatory consultant and clinical research expert with more than 20 years of experience supporting pharmaceutical, biotechnology, and medical device companies worldwide. He has contributed to over 75 clinical trials across diverse therapeutic areas and has extensive expertise in FDA regulations, INDs, NDAs, BLAs, clinical development strategy, GCP compliance, regulatory submissions, and global product development.
Drawing upon years of practical regulatory experience, Dr. Kumar will explain not only what the new FDA guidance says but also how organizations can implement its recommendations effectively within real-world clinical development programs.
Webinar Fee
Prices are in US Dollars.
The registration fee includes: The live webinar & all related course materials.
Terms & Conditions to register for the Webinar
Your Registration for the workshop is subject to following terms and conditions. If you need any clarification before registering for this webinar please email us at info@fdamap.com
Payment
We accept credit card, debit card, and PayPal.
Cancellations & Substitutions:
Written cancellations through fax or email (from the person who has registered for this conference) received at least 5 business days prior to the start date of the event will receive a refund — less a $30 administration fee. No cancellations will be accepted — nor refunds issued — within 5 business days before the start date of the event. You may however, choose to substitute the webinar for which you are registered with some other webinar in the future.
On request by email or fax (before the seminar) a credit for the amount paid minus administration fees ($30) will be transferred to any future FDA Map event and a credit note will be issued. No-shows will be charged the full amount.
Webinar material will be uploaded on the website 24 hours before the scheduled date of the webinar. In case it is not available on the website due to some technical issues, we will email the material a few hours before the start of the webinar.
In the event FDA Map cancels the webinar, FDA Map will issue a full refund to all the registrants for that webinar. Some topics and speakers may be subject to change without notice.
